1
|
Vannier C, Martens U, Bleckmann A, Zaiss M, Burkhart N, Decker T, Kaldune S, Langer C, Looß M, Hillebrand L, Vahtrik O, Frank M, Niemeier B, Potthoff K, Kasenda B. 67P Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023] Open
|
2
|
Vannier C, Jermann P, Matter M, Läubli H, Grebhardt S, Wright P, Kasenda B, Marschner N. 70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Martens U, Schröder J, Sellmann L, Reiser M, Frank-Gleich S, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Woerner S, Zacharias S, Marschner N, Kasenda B, Vannier C. 76P Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Vannier C, Völkel A, Martens U, Decker T, Köchling G, Lange S, Von der Heyde E, Emde TO, Wortmann A, Grunewald R, Frank M, Niemeier B, Flum M, Kasenda B. 31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.01.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Kasenda B, König D, Manni M, Ritschard R, Duthaler U, Bartoszek E, Bärenwaldt A, Deuster S, Hutter G, Cordier D, Mariani L, Hench J, Frank S, Krähenbühl S, Zippelius A, Rochlitz C, Mamot C, Wicki A, Läubli H. Targeting immunoliposomes to EGFR-positive glioblastoma. ESMO Open 2022; 7:100365. [PMID: 34998092 PMCID: PMC8741448 DOI: 10.1016/j.esmoop.2021.100365] [Citation(s) in RCA: 35] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 12/03/2021] [Accepted: 12/08/2021] [Indexed: 12/12/2022] Open
Abstract
Background We assessed the capacity of epidermal growth factor receptor (EGFR)-targeted immunoliposomes to deliver cargo to brain tumor tissue in patients with relapsed glioblastoma harboring an EGFR amplification. We aimed to assess the tolerability and effectiveness of anti-EGFR immunoliposomes loaded with doxorubicin (anti-EGFR ILs-dox) in glioblastoma multiforme patients. Patients and methods Patients with EGFR-amplified, relapsed glioblastoma were included in this phase I pharmacokinetic trial. Patients received up to four cycles of anti-EGFR ILs-dox. Twenty-four hours later, plasma and cerebrospinal fluid (CSF) samples were obtained. In addition, we also treated three patients with anti-EGFR ILs-dox before resection of their relapsed glioblastoma. Doxorubicin concentrations were measured in plasma, CSF, and tumor tissue. Safety and efficacy parameters were also obtained. Results There were no or negligible levels of doxorubicin found in the CSF demonstrating that anti-EGFR ILs-dox are not able to cross the blood–brain barrier (BBB). However, significant levels were detected in glioblastoma tissue 24 h after the application, indicating that the disruption of BBB integrity present in high-grade gliomas might enable liposome delivery into tumor tissue. No new safety issues were observed. The median progression-free survival was 1.5 months and the median overall survival was 8 months. One patient undergoing surgery had a very long remission suggesting that neoadjuvant administration may have a positive effect on outcome. Conclusions We clearly demonstrate that anti-EGFR-immunoliposomes can be targeted to EGFR-amplified glioblastoma and cargo—in this case doxorubicin—can be delivered, although these immunoliposomes do not cross the intact BBB. (The GBM-LIPO trial was registered as NCT03603379). Human pharmacokinetic and pharmacodynamic data for EGFR-targeted immunoliposomes. Demonstration of delivery of immunoliposomes to glioblastoma tissue. EGFR as a target to deliver drug-containing nanoparticles to glioma tissue.
Collapse
Affiliation(s)
- B Kasenda
- Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland
| | - D König
- Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
| | - M Manni
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - R Ritschard
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - U Duthaler
- Division of Clinical Pharmacology, University Hospital Basel, Basel, Switzerland
| | - E Bartoszek
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - A Bärenwaldt
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - S Deuster
- Hospital Pharmacy, University Hospital Basel, Basel, Switzerland
| | - G Hutter
- Neurosurgery, University Hospital Basel, Basel, Switzerland
| | - D Cordier
- Neurosurgery, University Hospital Basel, Basel, Switzerland
| | - L Mariani
- Neurosurgery, University Hospital Basel, Basel, Switzerland
| | - J Hench
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - S Frank
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - S Krähenbühl
- Division of Clinical Pharmacology, University Hospital Basel, Basel, Switzerland
| | - A Zippelius
- Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - C Rochlitz
- Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - C Mamot
- Division of Medical Oncology, Cantonal Hospital, Aarau, Switzerland
| | - A Wicki
- Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
| | - H Läubli
- Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
| |
Collapse
|
6
|
Schorb E, Kasenda B, Ihorst G, Fricker H, Holl H, Finke J, Illerhaus G. BICENTRIC PILOT STUDY ON AGE-ADAPTED HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA PATIENTS > 65 YEARS - MARiTA TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.81_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- E. Schorb
- Department of Hematology and Oncology; Faculty of Medicine, University of Freiburg; Freiburg Germany
| | - B. Kasenda
- Department of Hematology; Oncology and Palliative Care, Klinikum Stuttgart; Stuttgart Germany
| | - G. Ihorst
- Clinical Trials Unit; Faculty of Medicine, University of Freiburg; Freiburg Germany
| | - H. Fricker
- Department of Hematology and Oncology; Faculty of Medicine, University of Freiburg; Freiburg Germany
| | - H. Holl
- Department of Hematology; Oncology and Palliative Care, Klinikum Stuttgart; Stuttgart Germany
| | - J. Finke
- Department of Hematology and Oncology; Faculty of Medicine, University of Freiburg; Freiburg Germany
| | - G. Illerhaus
- Department of Hematology; Oncology and Palliative Care, Klinikum Stuttgart; Stuttgart Germany
| |
Collapse
|
7
|
Herbrand A, Schmitt A, Joerger M, Hemkens L, Kasenda B. OFF-LABEL USE IN LYMPHOMA PATIENTS IN SWITZERLAND. Hematol Oncol 2019. [DOI: 10.1002/hon.223_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A.K. Herbrand
- Department of Medical Oncology; University Hospital Basel; Basel Switzerland
| | - A.M. Schmitt
- Department of Medical Oncology; University Hospital Basel; Basel Switzerland
| | - M. Joerger
- Department of Oncology and Hematology; Cantonal Hospital; St. Gallen Switzerland
| | - L.G. Hemkens
- Basel Institute for Clinical Epidemiology and Biostatistics; Department of Clinical Research, University Hospital Basel and University of Basel; Basel Switzerland
| | - B. Kasenda
- Department of Hematology/Oncology and Palliative Care; Klinikum Stuttgart; Stuttgart Germany
| |
Collapse
|
8
|
Rothschild S, Helfenstein S, Riesterer O, Meier U, Papachristofilou A, Kasenda B, Pless M. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017; 31:2623-2629. [PMID: 28559537 DOI: 10.1038/leu.2017.170] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/08/2017] [Accepted: 05/15/2017] [Indexed: 01/08/2023]
Abstract
To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2 and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.
Collapse
Affiliation(s)
- B Kasenda
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.,Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - G Ihorst
- Clinical Trials Unit, Medical Centre - University of Freiburg, Freiburg, Germany
| | - R Schroers
- Department of Medicine, Hematology and Oncology, Ruhr-University of Bochum, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany
| | - A Korfel
- Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine, Berlin, Germany
| | - I Schmidt-Wolf
- Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany
| | - G Egerer
- Department of Haematology and Oncology, Heidelberg University, Heidelberg, Germany
| | - L von Baumgarten
- Department of Neurology, University Hospital Munich LMU, Munich, Germany
| | - A Röth
- Medical Faculty, Department of Haematology, University of Duisburg-Essen, Essen, Germany
| | - J Bloehdorn
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - R Möhle
- Department of Haematology and Oncology, University Tübingen, Tübingen, Germany
| | - M Binder
- Department of Oncology and Hematology, University of Hamburg, Hamburg, Germany
| | - U Keller
- III Medical Department, Technische Universität München, Munich, Germany
| | - M Lamprecht
- Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
| | - M Pfreundschuh
- Klinik für Innere Medizin I, Universität des Saarlandes, Homburg, Germany
| | - E Valk
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany
| | - H Fricker
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - E Schorb
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - K Fritsch
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - J Finke
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - G Illerhaus
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.,Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| |
Collapse
|
10
|
Moschetta M, Kasenda B, Mak G, Voskoboynik M, Martynyuk N, Rafii S, Formica V, Arkenau HT. Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.28] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 2016; 114:256-61. [PMID: 26794281 PMCID: PMC4742588 DOI: 10.1038/bjc.2015.467] [Citation(s) in RCA: 220] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Revised: 11/12/2015] [Accepted: 12/07/2015] [Indexed: 01/20/2023] Open
Abstract
Background: Treatment with programmed death receptor-1 (PD-1) antibodies is associated with high response rates in patients with advanced melanoma. Reliable markers for early response and outcome are still sparse. Methods: We evaluated 66 consecutive patients with advanced/metastatic melanoma treated with nivolumab or pembrolizumab between 2013 and 2014. The main objectives of this study were to investigate whether, first, serum lactate dehydrogenase (LDH) at baseline (normal vs above the upper limit of normal) correlates with overall survival (OS), and, second, whether the change of LDH during treatment predicts response before the first scan and OS in patients with an elevated baseline LDH. Results: After a median follow-up of 9 months, patients with an elevated baseline LDH (N=34) had a significantly shorter OS compared with patients with normal LDH (N=32; 6-month OS: 60.8% vs 81.6% and 12-month OS: 44.2% vs 71.5% (log-rank P=0.0292). In those 34 patients with elevated baseline LDH, the relative change during treatment was significantly associated with an objective response on the first scan: the 11 (32%) patients with partial remission had a mean reduction of −27.3% from elevated baseline LDH. In contrast, patients with progressive disease (N=15) had a mean increase of +39%. Patients with a relative increase over 10% from elevated baseline LDH had a significantly shorter OS compared with patients with ⩽10% change (4.3 vs 15.7 months, log-rank P<0.00623). Conclusions: LDH could be a useful marker at baseline and during treatment to predict early response or progression in patients with advanced melanoma who receive anti-PD-1 therapy.
Collapse
Affiliation(s)
- S Diem
- Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW36JJ, UK
| | - B Kasenda
- Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW36JJ, UK
| | - L Spain
- Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW36JJ, UK
| | - J Martin-Liberal
- Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW36JJ, UK.,Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - R Marconcini
- Department of Medical Oncology, Santa Chiara Hospital, via Roma 67, 56100 Pisa, Italy
| | - M Gore
- Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW36JJ, UK
| | - J Larkin
- Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW36JJ, UK
| |
Collapse
|
12
|
Schandelmaier S, Conen K, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Meerpohl JJ, Stegert M, Olu KK, Tikkinen KAO, Neumann I, Carrasco-Labra A, Faulhaber M, Mulla SM, Mertz D, Akl EA, Sun X, Bassler D, Busse JW, Ferreira-González I, Lamontagne F, Nordmann A, Gloy V, Raatz H, Moja L, Rosenthal R, Ebrahim S, Vandvik PO, Johnston BC, Walter MA, Burnand B, Schwenkglenks M, Hemkens LG, Bucher HC, Guyatt GH, Briel M, Kasenda B. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol 2015; 27:209. [PMID: 26612098 DOI: 10.1093/annonc/mdv559] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Affiliation(s)
- S Schandelmaier
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland Academy of Swiss Insurance Medicine, University Hospital Basel, Basel, Switzerland
| | - K Conen
- Department of Oncology, University Hospital of Basel, Switzerland
| | - E von Elm
- Cochrane Switzerland, Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland
| | - J J You
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Medicine, McMaster University, Hamilton, Canada
| | - A Blümle
- German Cochrane Centre, Medical Center-University of Freiburg, Freiburg, Germany
| | - Y Tomonaga
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - R Saccilotto
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - A Amstutz
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - T Bengough
- Department of Health and Society, Austrian Federal Institute for Health Care, Vienna, Austria
| | - J J Meerpohl
- German Cochrane Centre, Medical Center-University of Freiburg, Freiburg, Germany
| | - M Stegert
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - K K Olu
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - K A O Tikkinen
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Departments of Urology and Public Health, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - I Neumann
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Internal Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
| | - A Carrasco-Labra
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Evidence-Based Dentistry Unit, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
| | - M Faulhaber
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| | - S M Mulla
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| | - D Mertz
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Medicine, McMaster University, Hamilton, Canada Michael G. DeGroote Institute for Infectious Diseases Research, McMaster University, Hamilton, Canada
| | - E A Akl
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Internal Medicine, American University of Beirut, Beirut, Lebanon Department of Medicine, State University of New York at Buffalo, Buffalo, USA
| | - X Sun
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - D Bassler
- Department of Neonatolgy, University Hospital Zurich, Zurich, Switzerland
| | - J W Busse
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Anesthesia, McMaster University, Hamilton, Canada Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Canada
| | - I Ferreira-González
- Epidemiology Unit, Department of Cardiology, Vall d'Hebron Hospital and CIBER de Epidemiología y Salud Publica (CIBERESP), Barcelona, Spain
| | - F Lamontagne
- Centre de Recherche Clinique du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Canada
| | - A Nordmann
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - V Gloy
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland
| | - H Raatz
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - L Moja
- IRCCS Orthopedic Institute Galeazzi, Milan, Italy
| | - R Rosenthal
- Department of Surgery, University Hospital Basel, Switzerland
| | - S Ebrahim
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Anesthesia and Pain Medicine, Hospital for Sick Children Research Institute, Hospital for Sick Children, Toronto, Canada Department of Anesthesia, McMaster University, Hamilton, Canada Stanford Prevention Research Center, Stanford University, Stanford, USA
| | - P O Vandvik
- Department of Medicine, Innlandet Hospital Trust-Division Gjøvik, Oppland, Norway
| | - B C Johnston
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Anesthesia and Pain Medicine, Hospital for Sick Children Research Institute, Hospital for Sick Children, Toronto, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
| | - M A Walter
- Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland
| | - B Burnand
- Cochrane Switzerland, Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland
| | - M Schwenkglenks
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - L G Hemkens
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - H C Bucher
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland
| | - G H Guyatt
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| | - M Briel
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Department of Clinical Research, University of Basel, Switzerland
| | - B Kasenda
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Switzerland Department of Oncology, University Hospital of Basel, Switzerland Department of Medical Oncology, Royal Marsden Hospital, London, UK
| | | |
Collapse
|
13
|
Schandelmaier S, Conen K, von Elm E, You JJ, Blümle A, Tomonaga Y, Amstutz A, Briel M, Kasenda B. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol 2015; 26:1966-1973. [PMID: 26133966 DOI: 10.1093/annonc/mdv283] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Accepted: 06/24/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Information about the impact of cancer treatments on patients' quality of life (QoL) is of paramount importance to patients and treating oncologists. Cancer trials that do not specify QoL as an outcome or fail to report collected QoL data, omit crucial information for decision making. To estimate the magnitude of these problems, we investigated how frequently QoL outcomes were specified in protocols of cancer trials and subsequently reported. DESIGN Retrospective cohort study of RCT protocols approved by six research ethics committees in Switzerland, Germany, and Canada between 2000 and 2003. We compared protocols to corresponding publications, which were identified through literature searches and investigator surveys. RESULTS Of the 173 cancer trials, 90 (52%) specified QoL outcomes in their protocol, 2 (1%) as primary and 88 (51%) as secondary outcome. Of the 173 trials, 35 (20%) reported QoL outcomes in a corresponding publication (4 modified from the protocol), 18 (10%) were published but failed to report QoL outcomes in the primary or a secondary publication, and 37 (21%) were not published at all. Of the 83 (48%) trials that did not specify QoL outcomes in their protocol, none subsequently reported QoL outcomes. Failure to report pre-specified QoL outcomes was not associated with industry sponsorship (versus non-industry), sample size, and multicentre (versus single centre) status but possibly with trial discontinuation. CONCLUSIONS About half of cancer trials specified QoL outcomes in their protocols. However, only 20% reported any QoL data in associated publications. Highly relevant information for decision making is often unavailable to patients, oncologists, and health policymakers.
Collapse
Affiliation(s)
- S Schandelmaier
- Basel Institute for Clinical Epidemiology and Biostatistics; Academy of Swiss Insurance Medicine
| | - K Conen
- Department of Oncology, University Hospital of Basel, Basel
| | - E von Elm
- Cochrane Switzerland, Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland
| | - J J You
- Department of Clinical Epidemiology and Biostatistics; Department of Medicine, McMaster University, Hamilton, Canada
| | - A Blümle
- German Cochrane Centre, Medical Center-University of Freiburg, Freiburg, Germany
| | - Y Tomonaga
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich
| | - A Amstutz
- Basel Institute for Clinical Epidemiology and Biostatistics
| | - M Briel
- Basel Institute for Clinical Epidemiology and Biostatistics; Department of Clinical Epidemiology and Biostatistics; Department of Clinical Research, University of Basel, Basel, Switzerland
| | - B Kasenda
- Basel Institute for Clinical Epidemiology and Biostatistics; Department of Oncology, University Hospital of Basel, Basel; Department of Medical Oncology, Royal Marsden Hospital, London, UK.
| | | |
Collapse
|
14
|
Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Ann Oncol 2015; 26:608-11. [DOI: 10.1093/annonc/mdv002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
15
|
Kasenda B, Ferreri AJM, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 2015; 26:1305-13. [PMID: 25701456 DOI: 10.1093/annonc/mdv076] [Citation(s) in RCA: 121] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2014] [Accepted: 02/10/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND To investigate prognosis and effects of first-line therapy in elderly primary central nervous system lymphoma (PCNSL) patients. PATIENTS AND METHODS A systematic review of studies about first-line therapy in immunocompetent patients ≥60 years with PCNSL until 2014 and a meta-analysis of individual patient data from eligible studies and international collaborators were carried out. RESULTS We identified 20 eligible studies; from 13 studies, we obtained individual data of 405 patients, which were pooled with data of 378 additional patients (N = 783). Median age and Karnofsky Performance Score (KPS) was 68 years (range: 60-90 years) and 60% (range: 10%-100%), respectively. Treatments varied greatly, 573 (73%) patients received high-dose methotrexate (HD-MTX)-based therapy. A total of 276 patients received whole-brain radiotherapy (median 36 Gy, range 28.5-70 Gy). KPS ≥ 70% was the strongest prognostic factor for mortality [hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.41-0.62]. After a median follow-up of 40 months, HD-MTX-based therapy was associated with improved survival (HR 0.70, 95% CI 0.53-0.93). There was no difference between HD-MTX plus oral chemotherapy and more aggressive HD-MTX-based therapies (HR 1.39, 95% CI 0.90-2.15). Radiotherapy was associated with an improved survival, but correlated with an increased risk for neurological side-effects (odds ratio 5.23, 95% CI 2.33-11.74). CONCLUSIONS Elderly PCNSL patients benefit from HD-MTX-based therapy, especially if combined with oral alkylating agents. More aggressive HD-MTX protocols do not seem to improve outcome. WBRT may improve outcome, but is associated with increased risk for neurological side-effects. Prospective trials for elderly PCNSL patients are warranted.
Collapse
Affiliation(s)
- B Kasenda
- Department of Oncology, University Hospital of Basel, Basel Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - A J M Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
| | - E Marturano
- Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
| | - D Forst
- Partners Neurology Residency Program, Harvard Medical School, Boston, USA
| | - J Bromberg
- Department of Neuro-Oncology, Daniel den Hoed Cancer Center, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - H Ghesquieres
- Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
| | - C Ferlay
- Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
| | - J Y Blay
- Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
| | - K Hoang-Xuan
- Department of Neurology Mazarin, LOC National Expert Center, APHP, IHU, UPMC, CRICM, GH Pitié-Salpêtrière, Paris, France
| | - E J Pulczynski
- Department of Haematology, Nordic Lymphoma Group, University Hospital Aarhus, Aarhus, Denmark
| | - A Fosså
- Norwegian Department of Oncology, Nordic Lymphoma Group, Radium Hospital, Oslo, Norway
| | - Y Okoshi
- Faculty of Medicine, Department of Hematology, University of Tsukuba, Tsukuba, Japan
| | - S Chiba
- Faculty of Medicine, Department of Hematology, University of Tsukuba, Tsukuba, Japan
| | - K Fritsch
- Department of Hematology/Oncology, University Hospital Freiburg, Freiburg, Germany
| | - A Omuro
- Department of Neurology Mazarin, LOC National Expert Center, APHP, IHU, UPMC, CRICM, GH Pitié-Salpêtrière, Paris, France
| | - B P O'Neill
- Department of Neurology, Mayo Medical School, Rochester, USA
| | - O Bairey
- Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Tel Aviv Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - S Schandelmaier
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - V Gloy
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - N Bhatnagar
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| | - S Haug
- Psychiatry and Psychotherapy, University Hospital Freiburg, Freiburg
| | - S Rahner
- Medical Faculty, University of Freiburg, Freiburg, Germany
| | - T T Batchelor
- Partners Neurology Residency Program, Harvard Medical School, Boston, USA Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, USA
| | - G Illerhaus
- Stuttgart Cancer Center, Eva-Mayr-Stihl Tumor Center, Stuttgart, Germany
| | - M Briel
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| |
Collapse
|
16
|
Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol 2012; 23:2670-2675. [PMID: 22473593 DOI: 10.1093/annonc/mds059] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND High-dose chemotherapy followed by autologous stem-cell transplantation (HCT-ASCT) is a promising approach in eligible patients with primary central nervous system lymphoma (PCNSL). We report long-term data of patients who were treated according to HCT-ASCT containing protocols. PATIENTS AND METHODS We analyzed survival and relapse rates in 43 (<67 years) immunocompetent patients with newly diagnosed PCNSL being treated according to two different high-dose methotrexate-based protocols followed by high-dose carmustine/thiotepa (BCNU/TT) plus ASCT (±whole brain irradiation). Analysis was conducted for all patients (intention-to-treat) and those patients who actually received HCT-ASCT (per-protocol). RESULTS Thirty-four patients achieved complete remission, of those 12 relapsed (35%), while 6 of them relapsed 5 years after diagnosis. After a median follow-up of 120 months, median overall survival (OS) was reached after 104 months. Two- and 5-year OS was 81% and 70% and 2- and 5-year event-free survival (EFS) was 81% and 67%, respectively. In per-protocol analysis (N = 34), 5-year OS and EFS was 82% and 79%, respectively. HCT-ASCT associated related mortality was not observed. CONCLUSIONS Sequential high-dose MTX containing chemotherapy followed by high-dose carmustine/thiotepa plus ASCT (±whole brain irradiation) is safe and leads to high survival rates in eligible patients with newly diagnosed PCNSL.
Collapse
Affiliation(s)
- B Kasenda
- Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - E Schorb
- Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
| | - K Fritsch
- Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
| | - J Finke
- Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
| | - G Illerhaus
- Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany.
| |
Collapse
|
17
|
Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, Haug S, Ihorst G, Finke J, Illerhaus G. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011; 22:2080-2085. [PMID: 21303800 DOI: 10.1093/annonc/mdq712] [Citation(s) in RCA: 100] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP). DESIGN AND METHODS PCNSL patients ≥65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), methotrexate (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, procarbazine (60 mg/m(2) orally, days 2-11), and lomustine (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were overall survival (OS) and progression-free survival (PFS). RESULTS Twenty-eight patients were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) patients. Response was not assessed in two patients. Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and OS was 31%. CONCLUSION R-MCP regimen is well tolerated and active in elderly patients with newly diagnosed PCNSL.
Collapse
Affiliation(s)
- K Fritsch
- Department of Hematology and Oncology
| | - B Kasenda
- Department of Hematology and Oncology
| | - C Hader
- Department of Neuroradiology
| | - G Nikkhah
- Department of Stereotactic and Functional Neurosurgery
| | - M Prinz
- Department of Neuropathology, Freiburg University Medical Center, Freiburg, Germany
| | - V Haug
- Department of Hematology and Oncology
| | - S Haug
- Department of Hematology and Oncology
| | - G Ihorst
- Department of Hematology and Oncology
| | - J Finke
- Department of Hematology and Oncology
| | | |
Collapse
|